Product Development Costs. SPL shall, at SPL’s expense, be responsible for conducting all development of Agreement Compounds, Agreement Products, Schering Compounds, and all commercialization of Agreement Products.
Product Development Costs. Research of new product ideas and enhancements to existing products are charged to expense as incurred. The Company accounts for income taxes using the liability method. Under the liability method, deferred tax liabilities and assets are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company records liabilities, where appropriate, for all uncertain income tax positions. The Company recognizes potential accrued interest and penalties related to unrecognized tax benefits within operations as income tax expense. Other comprehensive loss as of June 30, 2015 and December 31, 2014, consists of unrealized gains and losses on marketable securities categorized as available-for-sale and foreign currency translation adjustments. Basic net loss per share is calculated using the weighted average shares of common stock outstanding, excluding treasury stock. Diluted net loss per share is calculated using the weighted average number of common and potentially dilutive common shares outstanding, excluding treasury stock, during the period, using the treasury stock method for stock options. As a result of the Company’s net loss position at both June 30, 2015 and 2014, there is no dilution. The Company has one operating segment, online advertising. While the Company operates under one operating segment, management reviews revenue under two product offerings—Advertiser Networks and Publisher Solutions. As of June 30, 2015 and December 31, 2014, the Company’s accounts receivable and deferred revenue are primarily related to the online advertising segment. All long-lived assets are located in the United States and Canada. On January 2, 2014 we adopted guidance issued by the Financial Accounting Standards Board (“FASB”), ASU 2013-04, “Liabilities – Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation is Fixed at the Reporting Date”, an amendment providing guidance for the recognition, measurement, and disclosure of obligations resulting from joint and several liability arrangements for which the total amount of the obligation is fixed at the reporting date. Adoption of this new guidance had no impact on the Company’s consolidated financial pos...
Product Development Costs. Research of new product ideas and enhancements to existing products are charged to expense as incurred. The Company accounts for income taxes using the liability method. Under the liability method, deferred tax liabilities and assets are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company records liabilities, where appropriate, for all uncertain income tax positions. The Company recognizes potential accrued interest and penalties related to unrecognized tax benefits within operations as income tax expense. Other comprehensive loss as of June 30, 2015, December 31, 2014, and December 31, 2013, consists of unrealized gains and losses on marketable securities categorized as available-for-sale and foreign currency translation adjustments. Basic net loss per share is calculated using the weighted average shares of common stock outstanding, excluding treasury stock. Diluted net loss per share is calculated using the weighted average number of common and potentially dilutive common shares outstanding, excluding treasury stock, during the period, using the treasury stock method for stock options. As a result of the Company’s net loss position at June 30, 2015, December 31, 2014 and 2013, there is no dilution. The Company has one operating segment, online advertising. While the Company operates under one operating segment, management reviews revenue under five lines of business: (i) Clickable, (ii) LookSmart AdCenter, (iii) Nxxxxxxx.xx, (iv) ShopWiki and (v) web searches. As of December 31, 2014 and December 31, 2013, the Company’s accounts receivable and deferred revenue are primarily related to the online advertising segment. All long-lived assets are located in the United States and Canada. As of June 30, 2015, the Company’s accounts receivable and deferred revenue are primarily related to the online advertising segment. All long-lived assets are located in the United States and Canada. On January 2, 2014 we adopted guidance issued by the Financial Accounting Standards Board (“FASB”), ASU 2013-04, “Liabilities – Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation is Fixed at the Reporting Date”, an amendment providing gui...
Product Development Costs. Schering shall, at Schering’s expense, be responsible for conducting all development of Agreement Compounds, Agreement Products, Schering Compounds, and all commercialization of Agreement Products.
Product Development Costs. All Product Development Costs are expressly excluded from the Contribution Income sharing concept and, subject to Section 2.1(c) above, shall be shared by the parties as follows.
(a) Subject to variances in patient accrual rates, the parties agree that the anticipated budget for Product Development Costs in calendar year 1998 shall not exceed [***]. The parties further agree that, subject to variances in patient accrual rates, the anticipated budget for Product Development Costs in calendar year 1999 for the clinical trials already in progress or ready to be started and for the ACCENT study is estimated at [***]. Schering-Plough shall make a payment of [***] to Centocor by wire transfer on or before [***]. Schering-Plough's obligation to pay for Product Development Costs incurred during 1998 and 1999 with respect to such studies shall be capped, unless the Product Committee elects to initiate additional clinical studies during such calendar years or the Product Committee otherwise approves additional Product Development Costs to be incurred in such calendar years. To the extent that either party exceeds the agreed upon budgeted Product Development Costs for such activities without the prior written approval of the Product Committee, such party shall be solely responsible for such excess expenditures which shall be excluded from Product Development Costs.
(b) In each successive Agreement Year after 1999 during the term of this Agreement, the parties shall agree upon a budget setting forth the estimated Product Development Costs for their respective development activities. To the extent that either party exceeds the agreed upon budgeted Product Development Costs for such activities without the prior written approval of the Product Committee, such party shall be solely responsible for such excess expenditures which shall be excluded from the calculation of any Excess Amount under Section 6.3(c).
(c) Within thirty (30) days following the end of each calendar quarter, each party will provide a written summary to the other party of its respective Product Development Costs for such calendar quarter. Such summary will include adequate and reasonable information to quantify the activities and costs and qualify the activities under the programs approved in accordance with Article IV. With respect to any such calendar quarter, the amount by which the total of one party's Product Development Costs exceeds the total of the other party's Product Development Costs is ref...
Product Development Costs. (a) VCD shall be responsible for the payment of all costs for Product development (“Product Development Costs”).
(b) OBI shall provide VCD with estimates for costs to be incurred and no costs shall be incurred by OBI until they have received seventy-five percent (75%) of the estimated costs.
(c) VCD shall reimburse OBI for the actual costs incurred within thirty (30) days of VCD’s receipt of a final expense report from OBI,which will include a 10% markup for administrative overhead..
(d) All intellectual property and Know-How generated from or in connection with Product Development shall be owned exclusively by OBI and shall be incorporated as part of the License granted to Licensee hereunder.
Product Development Costs dodo shall manage and fund further development of dodo Products at its discretion. Dodo shall be responsible for development of approximately ten (10) cosmetic products utilizing Axen for dodo's premium brand.
Product Development Costs. 11 3.2.1 General..................................................... 11 3.2.2 Quarterly Reports........................................... 11 3.3
Product Development Costs. Eos will [*****]. Medarex and Eos [*****] ------------------------- being pursued under Section E1, above. Internal costs incurred by the Parties for agreed upon activities in direct support of development will be shared equally by the Alliance at actual Fully-Burdened Costs without an additional xxxx-up by the Parties.
Product Development Costs. (a) During the portion of the Collaboration Period prior to the later of (i) [**] or (ii) the completion of [**] (the later of (i) or (ii), the “Cost Responsibility Transition Date”), Pfizer shall reimburse Spark for [**] percent ([**]%) of the Development Costs and [**] percent ([**]%) of the Manufacturing Costs incurred under Product Development Plan, in accordance with the Budget. To the extent that the actual total Development Costs and Manufacturing Costs for expenses incurred under Product CONFIDENTIAL EXECUTION VERSIONNovember 6, 2017 Development Plan expended prior to the end of the Collaboration Period exceed a cumulative aggregate of [**] U.S. dollars ($[**]) (the “Cap”), Pfizer will subject to Section 4.3.2(i) reimburse Spark for one hundred percent (100%) of the Development Costs and Manufacturing Costs in excess of the Cap; and thereafter if actual Development Costs and Manufacturing Costs exceed the Cap, Pfizer will, subject to the limitations set forth in Section 4.3.2(e), have final decision-making authority in the JSC with respect to any Disputed Matters. Following the Collaboration Period, Pfizer will pay all Development Costs and Manufacturing Costs.
(b) Beginning on the Cost Responsibility Transition Date and for the remainder of the Collaboration Period, Pfizer shall reimburse Spark for all Development Costs incurred under the Product Development Plan, in accordance with the Budget. Beginning on the Cost Responsibility Transition Date, Pfizer will, subject to the limitations set forth in Section 4.3.2(e), have final decision-making authority in the JSC with respect to any Disputed Matters.
(c) Following the Collaboration Period, Pfizer will be responsible for all Development Costs and Manufacturing Costs it incurs.”
